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Clinical Arrhythmias
The Risk of Atrial Arrhythmias in Inherited 
Primary Arrhythmia Syndromes 
The inherited primary arrhythmia syndromes (IPAS) are a 
heterogeneous group of diseases caused by mutations in genes 
encoding for cardiac ion channels. People affected by one 
of these inherited diseases have no overt structural cardiac 
abnormalities but are at higher risk of sudden cardiac death due to 
the occurrence of life-threatening ventricular arrhythmias.1 Cardiac 
channelopathies include Brugada syndrome (BrS), short and long 
QT syndromes (SQTS and LQTS), early repolarisation syndrome (ERS) 
and catecholaminergic polymorphic ventricular tachycardia (CPVT).1 
The vast majority of IPAS present with a specific ECG phenotype, 
characterised by an abnormal ventricular depolarisation and/or 
repolarisation phase, such as the coved-type ST-segment elevation 
in the right precordial leads, infero-lateral early repolarisation (ER), 
long QT and short QT intervals.1,2 These abnormalities reflect altered 
imbalance in ionic currents of cardiac myocytes, that may lead to 
development of ventricular arrhythmias such as monomorphic, 
polymorphic ventricular tachycardia (VT) or VF. 
Since the diagnostic ECG ventricular pattern of many IPAS is dynamic 
and often concealed, it is particularly difficult to estimate the prevalence 
of these diseases in the general population. However, most studies 
indicate that BrS is probably the most common with a prevalence 
ranging from 1:2,000 in Europe to 1:1,000 in Asian and south-east 
Pacific countries, followed by LQTS which has an estimated prevalence 
of four in 10,000 worldwide.1 BrS may present overlapping ECG and 
clinical features with ERS and an ER pattern in the infero-lateral leads 
with a J-point elevation ≥0.2 mV has been observed in up to 6% of 
community-based middle-aged subjects without BrS.3 SQTS and CPVT 
are the two rarest cardiac channelopathies with a prevalence of 2.7 in 
100,000 and 1 in 10,000, respectively, worldwide.1 
Both atrial and ventricular cardiomyocytes may express proteins 
encoded by the same mutated gene, which makes atrial arrhythmias 
common in patients with inherited primary arrhythmia syndromes.4 
Paroxysmal AF is by far the most common atrial arrhythmia observed 
in these patients, and is occasionally the first and only manifestation 
of an inherited cardiac ion channel dysfunction.2,5 
While the prevalence of paroxysmal AF in the young (aged <50 years) is 
0.1%, prevalence of AF is significantly higher among people with IPAS, 
ranging from 2% for patients with genetically proven LQTS to 30% for 
subjects with SQTS (Table 1).6–8 
In recent years, scientific evidence has been provided on the genetic 
basis of AF in the general population. Many monogenic mutations 
or rare variants have been identified.14 However, although useful 
in understanding the pathophysiology of AF, these mutations or 
rare variants have limited value in explaining the heritability of 
AF, accounting only for sporadic or familial cases of AF. Genome-
wide association studies for AF have identified 97 loci that are 
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significantly associated with an increased risk of AF that might 
be potential signals for the causative genes.14 It is still unknown 
the specific role of genetic variants in enhancing the risk of atrial 
arrhythmias in IPAS.
Long QT Syndrome
Eleven LQTS susceptibility genes have been described so far. However, 
mutations in three genes (KCNQ1-mediated LQT1, KCNH2-mediated 
LQT2, and SCN5A-mediated LQT3) account for 75% of clinically definite 
LQTS. It has been shown that a patient with LQTS has a 17-fold higher 
risk of experiencing AF before the age of 50 compared with population-
based individuals (RR 17.5, CI 2.2–139.6).7 Of patients with genetically 
proven LQTS and AF, 63% present with a loss-of-function mutation 
in KCNQ1.7 
Kirchhoff et al. reported that patients with LQTS have altered atrial 
electrophysiology due to the prolongation of the atrial action potential 
and the atrial effective refractory period (Figure 1). These alterations, 
possibly determined by a dysfunction of KCNQ1-encoded IKs, lead to 
an enhanced susceptibility for an atrial form of torsades de pointes, 
having a longer cycle length, but resembling AF on the surface ECG 
(Table 2).9 Similarly, Satoh and Zipes reported the effects of caesium 
chloride, a potassium channel blocker, in determining polymorphic 
atrial tachyarrhythmias by producing early after-depolarisations in 
canines. Based on these observations, it might be speculated that 
patients with LQTS present a similar arrhytmogenic platform for the 
development of both ventricular and atrial tachyarrhythmias.10
Short QT Syndrome
Three gain-of-function gene mutations encoding for cardiac potassium 
channels have been associated with SQTS: KCNH2 (SQT1), KCNQ1 
(SQT2) and KCNJ2 (SQT3). AF is common in patients with SQTS and in 
half of all cases it is the first clinical manifestation of the syndrome.8 
The potential physio-pathological mechanism responsible in SQTS for 
both atrial and ventricular arrhythmias is shortening of the refractory 
period due to a gain of function of potassium channels.11 
Early Repolarisation Syndrome and 
Catecholaminergic Polymorphic Ventricular 
Tachycardia  
No specific information is available on atrial arrhythmias in patients 
with ERS and CPVT. Junttila et al. reported that paroxysmal AF occurs 
in 15% of middle-aged subjects with an infero-lateral ER pattern.12 A 
gain-of-function in gene encoding in the cardiac potassium channel 
(Kir6.1) is associated with both increased AF susceptibility and ER, 
indicating a role for the ion channel function in both ventricular 
and atrial repolarisation.13 Ventricular pathophysiological mechanisms 
leading to ERS are still controversial and no specific studies have been 
carried out to assess the atrial electrophysiological abnormalities in 
these patients.
Atrial tachyarrhythmias seem to be rare in patients with CPVT. 
Exercise-induced supraventricular arrhythmias have been only 
sporadically reported in patients with CPVT and no further specific 
data have been reported.1,4  More than half of  CPVT cases 
are caused by autosomal-dominant missense mutations in the 
ryanodine receptor (RyR2), which is the major calcium (Ca2+) release 
channel on the sarcoplasmic reticulum (SR) required for excitation-
contraction coupling in cardiac muscle.15 In mouse models of CPVT, 
it has been shown that RyR2-mediated diastolic SR Ca2+ leak in atrial 
myocytes is associated with AF.16 Moreover, most experimental 
studies agree that RyR2 phosphorylation by protein kinase A and 
Ca2+ calmodulin-dependent protein kinase II can potentiate SR Ca2+ 
leak, which is associated with ectopic activity and susceptibility to 
arrhythmias in CPVT.17 
Atrial Arrhythmias in Brugada Syndrome
The ECG hallmark of BrS is the presence of a coved-type ST-segment 
elevation of >2 mm (Brugada type 1 ECG) in at least one right 
precordial lead (V1 and V2), placed in a standard or superior position.2 
The Brugada type 1 ECG can be concealed, becoming apparent only 
under certain conditions such as fever or enhanced vagal tone. Most 
prominent ECG changes usually appear just before the onset of 
ventricular arrhythmias. The Brugada type 1 ECG is required for the 
diagnosis of BrS and, in the case of a non-diagnostic baseline ECG, can 
be unmasked by the IV administration of sodium channel blockers, 
such as ajmaline or flecainide.2
 
The ECG phenotypic expression of BrS is determined by the 
presence of an outward shift of the balance in repolarising currents 
Figure 1: Effects of Different Cardiac Channelopathies on 
Atrial Electrophysiology
Brugada syndrome 
Catecholaminergic polymorphic 
ventricular tachycardia
Duration of action potential
Atrial effective refractory period
 Intra-atrial conduction
Sinus node function
Brugada syndrome
Long QT syndrome
Short QT syndrome
Long QT syndrome Short QT syndrome
Brugada syndrome
Table 1: Prevalence of Atrial Arrhythmias in Inherited 
Primary Arrhythmia Syndromes
Prevalence Atrial Arrhythmias 
Rate
Long QT syndrome 4 in 10,000 2%
Short QT syndrome 2.7 in 100,000 30%
Brugada syndrome 1 in 2,000 20%
Early repolarisation syndrome Unknown 15%
Catecholaminergic polymorphic 
ventricular tachycardia
1 in 10,000 Unknown
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at the level of the right ventricular outflow tract (RVOT), caused by 
a decrease in sodium or calcium channel currents or an increase 
in outward potassium currents, which creates a notch in the 
action potential of the epicardium resulting in a transmural voltage 
gradient.18 Although the pathophysiological origin of the syndrome 
is still under debate, there is general consensus that the presence 
of functional abnormalities in the epicardial RVOT leads to the 
ventricular phenotypic manifestation of the disease. Nademanee et 
al. observed that abnormal fractionated late potentials can be found 
in the RVOT epicardium of people with BrS and can be eliminated 
by catheter ablation.19 These findings were later confirmed by 
Pappone et al., who reported that epicardial mapping and ablation 
of BrS can be safely performed and its efficacy can be confirmed 
by post-ablation remapping and flecainide testing, and results in the 
elimination of abnormal substrate and simultaneous disappearance 
of the typical BrS ECG pattern and no further inducibility of VT/VF.20 
Pharmacological therapy with quinidine together with ICD implantation 
can be used as an alternative to catheter ablation in high-risk 
patients.21 The efficacy of quinidine is based on its blocking effects on 
Ito currents (transient outward potassium currents) and can be tested 
by the absence of VT/VF inducibility during programmed ventricular 
stimulation.21 Moreover, it has been recently reported in a series 
of 20 BrS patients undergoing RVOT endomyocardial biopsy that 
pathologic findings with myocardial inflammation were present in 75% 
of cases, which prompts the question of whether a combination of 
electrical and structural abnormalities can explain the arrhythmogenic 
substrate of BrS.22
Among people with IPAS, BrS is the most genetically heterogeneous 
disease and has a considerable allelic heterogeneity: mutations in 
different genes can, in fact, lead to the same clinical manifestation and 
different mutations in each gene can eventually cause the disease. In 
addition, different gene mutations and variants can coexist and affect 
one or more subunits of the potassium, calcium and sodium channel 
structures.23 BrS has been associated with mutations in 19 different 
genes. Genetic abnormalities are found in up to 30% of genotyped 
patients with BrS.24
Paroxysmal AF is the most common supraventricular arrhythmia in 
patients with BrS, occurring in about 20% of cases.2,25 Paroxysmal AF 
represents a relevant clinical issue in BrS for several reasons. Patients 
with BrS who develop paroxysmal AF have a more severe phenotype 
and advanced disease process with higher incidence of syncopal 
episodes, spontaneous or induced sustained ventricular arrhythmias 
and spontaneous Brugada type 1 ECG.26,27 The incidence of AF is 
higher in patients with an ICD and up to 20% of these patients can 
experience inappropriate shocks because of AF with rapid ventricular 
response.28 Appropriate screening and the choice of the most 
appropriate type of device (single, dual-chamber or subcutaneous), 
together with careful programming, is necessary to correctly detect 
episodes of fast AF and reduce the rate of inappropriate shocks, 
which are significantly affecting the quality of life of these generally 
young patients. Moreover, patients with BrS who develop AF have a 
more frequent positive genetic test, but SCN5A mutation has been 
associated with prolonged atrial conduction time and AF induction at 
EPS, but not disease severity.29
 
The pharmacological treatment of paroxysmal AF in BrS is limited by 
being unable to use conventional AADs with sodium channel blocking 
properties, which might be pro-arrhythmic, exposing patients to the 
development of life-threatening arrhythmias. Indeed, according to 
the brugadadrugs.org website, flecainide, ajmaline, procainamide, 
pilsicainide, propafenone are drugs that should be strongly avoided 
because they have been associated with an enhanced risk of 
ventricular arrhythmias. Amiodarone, propanolol, verapamil and 
vernakalant should be preferentially avoided, while there is no mention 
on the use of sotalol, quinidine or other beta-blockers. However, the 
latter are underused and not well tolerated by these young patients 
due to their side-effects.
Although pulmonary vein (PV) isolation is currently the most 
widespread ablation strategy to treat patients with paroxysmal AF, 
the choice of the best invasive treatment in patients with BrS remains 
controversial. Indeed, in the general population, pathophysiological 
mechanisms leading to AF include adverse remodelling of the atrial 
electro-anatomical substrate and/or abnormal triggered activity.30 
Table 2: Atrial Arrhythmia Features in Long and Short QT Syndromes and Brugada Syndrome
Long QT Syndrome Short QT Syndrome Brugada Syndrome
ECG hallmark QTc >440/460 ms QTc <320 ms Coved type ST-segment elevation  
(Type 1 ECG)
Ventricular arrhythmia Polymorphic ventricular tachycardia Ventricular fibrillation Polymorphic ventricular tachycardia/
ventricular fibrillation
Atrial arrhythmia Polymorphic atrial tachycardia Atrial fibrillation Atrial fibrillation
Prevalence of AF LQT1: 2.4%
LQT2: 0%
LQT3: 1.7%
30% 20%
Mean age at AF diagnosis  
(years)
24 41 43
Known susceptibility genes 11 genes
(most commonly KCNQ1, KCNH2,  
SCN5A)
3 genes
(KCNH2, KCNQ1, KCNJ2)
19 genes
(SCN5A, KNCJ8, CACNA1C, CACNA2D1, 
CACNB2b, ABCC9, SCN10A, GpD1L,  
SCN1B, KCNE3, SCN3B, KCND3, RANGFR, 
SLMAP, SCN2B, PKP2, FGF12, HEY2, 
SEMA3A)
Response to drugs Ameliorative response: mexiletine
Proarrhythmic effects: amiodarone, sotalol
Ameliorative response: quinidine; 
propafenone
Ameliorative response: quinidine
Proarrhythmic effects: flecainide, 
propafenone
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Pulmonary vein ectopic activity has been established to be the 
main trigger of paroxysmal AF in patients without structural heart 
disease.31 Conversely, the pathophysiological mechanisms of AF in 
patients with BrS are still unknown and the role of PV triggering 
remains uncertain.32 Moreover, long-term results of AF ablation in 
patients with BrS are relatively poor when compared with similarly 
aged with lone AF.33 In fact, at a mean follow-up time of 22 months, 
nearly 65% of BrS patients were free from AF recurrences after having 
PV isolation.
The arrhythmogenic substrate of BrS might not be restricted to the 
ventricular level. Similar atrial changes could be the substrate for 
reentrant atrial tachyarrhythmias but have not been extensively studied. 
The presence of a prominent transient outward current in atria and the 
observation that episodes of AF are triggered by closely coupled atrial 
extrasystoles points to the possibility that a substrate similar to that 
responsible for ventricular arrhythmogenesis may also be responsible 
for the development of AF in patients with BrS.34 As for ventricular 
arrhythmias, the onset of AF in these patients is often preceded by 
fluctuations in autonomic tone and most AF episodes occur at night.29 
Vagal stimulation might reduce atrial conduction velocities and shorten 
the effective refractory period facilitating the induction of AF.29,30 
Apart from AF, BrS can coexist with other forms of atrial arrhythmias, 
including atrioventricular nodal reentrant tachycardia (AVNRT). 
Indeed, a concealed BrS ECG is present in 27% of patients presenting 
with AVNRT.35 In these cases, genetic variants known or suspected 
to cause loss of function of sodium channel current may provide 
a mechanistic link between AVNRT and BrS and predispose to the 
expression of both phenotypes.35 
Assessment of Atrial Electrical Activity in 
Patients with Brugada Syndrome
The baseline ECG of people who are prone to AF is easily obtainable 
and non-invasive and might reflect subclinical structural atrial 
abnormalities resulting from adverse remodelling of the atrial electro-
anatomical substrate.36,37 The P-wave on surface ECG represents 
atrial depolarisation and its duration may be a reliable non-invasive 
measurement of atrial conduction time. Previous studies have 
indicated that abnormal P-wave axis and long P-wave duration 
are strongly associated with an increased risk of AF.38,39 Moreover, 
P-wave indices which include a summary measure of duration, area 
and amplitude have been proposed to quantify the atrial electrical 
properties derived from the ECG, but they have shown only limited 
value in predicting AF occurrence.40 
The baseline ECG of patients with BrS reflects atrial electrical 
abnormalities resulting from the presence of an atrial channelopathy 
independently from the presence of previous episodes of AF. Patients 
with BrS have a longer P-wave duration compared with healthy 
controls.41,42 This anomaly might be due to the prolonged atrial action 
potential and increased intra-atrial conduction time reported by 
Kusano et al.25 These researchers did not find any significant difference 
in electrophysiological parameters, such as intra-atrial conduction 
time, duration of local atrial electrograms and atrial effective refractory 
period between BrS patients with type 1 and those with type 2 or 
type 3 determined by ECG. This shows the potential existence of a 
miscorrelation between the atrial and ventricular ECG phenotype, 
due to a different location or density of the imbalanced ion channels 
between atria and RVOT.
Recently, the existence of a concealed abnormal atrial phenotype 
has been documented in BrS without history of AF.43 Indeed, 
BrS patients without history of AF present with marked atrial 
electrical abnormalities which are even more pronounced when 
compared with those displayed by patients with paroxysmal AF. 
Moreover, the abnormal P-wave parameters can be detected even 
in the absence of an overt ventricular ECG phenotype, symptoms 
or SCN5A gene mutation, indicating the existence of a constant 
abnormal atrial phenotype and the presence of an atrial-ventricular 
phenotypic mismatch. The normal action potential in atria differs 
from that of the ventricle with respect to ion channel currents that 
contribute to resting membrane potential, phase 1 and phase 3 of 
the action potential.44
Experimental and clinical evidence suggests that there is 
heterogeneity of sodium currents among atrial and epicardial 
ventricular myocytes.44,45 Indeed, sodium current density is much 
greater in atrial versus ventricular cells and time constants for 
activation and inactivation are more rapid in atrial myocytes. These 
structural and pharmacological differences between atrial and 
ventricular sodium channels might be exaggerated in patients with 
an inherited sodium channel dysfunction and might explain the 
presence of a constantly abnormal atrial phenotype in people with 
BrS. High-density atrial endocardial mapping might be a useful tool to 
assess the presence of atrial electrical abnormalities in patients with 
BrS and documented atrial arrhythmias (Figure 2).
Conclusion and Future Perspectives
Available scientific data highlights the evidence that the 
arrhythmogenic substrate of an inherited ion channel dysfunction is 
not restricted to the ventricular level and similar abnormalities affect 
the atrial electrophysiological properties creating the substrate for 
the occurrence of reentrant atrial tachyarrhythmias. However, specific 
data on the involvement of the pathogenic process at the level of the 
atria are lacking and the relationship between the atrial and ventricular 
phenotype has not been deeply investigated in IPAS. 
A modelling approach to understanding inherited primary electrical 
disorders at the atrial level and detailed information about three-
dimensional distribution of atrial action potentials in people with 
cardiac channelopathies is of paramount importance. A full insight 
into atrial involvement in inherited primary arrhythmia syndromes 
provided by high-resolution ECG and mapping systems, and cardiac 
simulations might enrich our understanding of the pathophysiological 
Figure 2: Left Atrial High-Density Mapping of a Patient 
with Brugada Syndrome Undergoing AF Ablation
Low voltage area with abnormal electrograms 
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mechanisms underlying the development of atrial arrhythmias in these 
patients. In the last decade, particular attention has been focused 
on the development of atrial-selective drugs for the prevention of 
AF with the goal of avoiding ventricular pro-arrhythmic effects.45,46 
While atrial-selective sodium channel blockers with preferential atrial 
activity, such as ranolazine, might be useful in the management of AF 
in the general population, different effects of these drugs might be 
revealed in patients with a cardiac channelopathy. Indeed, the use of 
atrial selective sodium channel blockers may be pro-arrhythmic in BrS 
patients and may, eventually, lead to the development of AF.
 
In-depth characterisation of pathogenesis of atrial arrhythmias in 
IPAS might have significant clinical implications in the diagnostic and 
therapeutic management of a much larger group of individuals at risk 
of AF and, in general, in a very large group of patients affected by lone 
atrial fibrillation or other cardiac causes. 
Clinical Perspective
• The arrhythmogenic substrate of an inherited ion channel 
dysfunction is not restricted to the ventricular level and 
similar abnormalities affect the atrial electrophysiological 
properties creating the substrate for the occurrence of atrial 
tachyarrhythmias.
• Patients with Brugada syndrome present with a concealed 
abnormal atrial phenotype that can be detected even in the 
absence of an overt ventricular phenotype.
• In-depth characterisation of pathogenesis of atrial arrhythmias 
in patients with cardiac channelopathies have significant clinical 
implications in the diagnostic and therapeutic management 
and lead to a better understanding of the pathophysiological 
mechanisms and to a more appropriate individualised treatment.
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